NeuWave Medical, Inc., a Madison, Wisconsin-based medical device company focused on developing technology for use in the ablation of soft-tissue lesions, completed $25M Series C financing round.
The round was led by Versant Ventures with participation from existing investors H.I.G. BioVentures, Venture Investors and others. In conjunction with the funding, Kirk Nielsen, Managing Director at Versant Ventures, joined the NeuWave’s Board of Directors.
The company intends to use the capital to expand commercialization efforts and to develop the platform.
Led by Dan Sullivan, CEO, NeuWave Medical has developed an intelligent ablation system, a proven technology for the ablation of soft-tissue lesions, including primary and metastatic lesions in the lung, liver and kidney.
The system is currently being used by physicians in more than half of the top cancer institutions in the U.S.
The company also has a satellite office in Minneapolis, Minnesota.